| Literature DB >> 18387181 |
Dominik Mertz1, Nina Viktorin, Marcel Wolbers, Gerd Laifer, Bernd Leimenstoll, Ursula Fluckiger, Manuel Battegay.
Abstract
BACKGROUND: Infectious disease is often the reason for intravenous drug users being seen in a clinical setting. The objective of this study was to evaluate the appropriateness of treatment and outcomes for this patient population in a hospital setting.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18387181 PMCID: PMC2323004 DOI: 10.1186/1471-2334-8-42
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1Study population and frequency of relapses according to different treatment modalities in 344 hospitalizations among 216 IVDU*. IVDU = Intravenous drug users. n = Number of hospitalizations. ID = Infectious disease specialist. Rx = Prescribed treatment. * seen by an ID during a period of 5 years. † Not included in study: -Patients who did not require antibiotic. -Former IVDU who had stopped using narcotics at least two years prior to their admittance to the hospital and were not participating in an opioid maintenance program ††p = 0.03 (Rx according to guidelines vs. others)
Patient characteristics of 344 hospitalizations among 216 IVDU*
| Gender (male/female) (n = 344) | 67/33 | ||
| Participation in opioid maintenance program (information available in n = 270) | |||
| In a program = 253 | 93.7 | ||
| No program = 17 | 6.3 | ||
| Age (years) | (n = 344) | 38 | (18–58) |
| Body mass index (kg/m2) | (n = 212) | 20.9 | (14–40) |
| Temperature at admission (°C) | (n = 328) | 38.6 | (35.3–42) |
| C-reactive protein at admission (mg/l) | (n = 342) | 121.5 | (0.7–514) |
| White blood cell count (× 109/l) | (n = 342) | 10.9 | (0.1–80.4) |
| Length of hospital stay (days) | (n = 344) | 17 | (1–125) |
* seen by an ID during a period of 5 years.
†Data on opioid substitution program participation, body mass index, temperature, white cell count, and C-reactive protein was not available for all patients.
IVDU = Intravenous drug user.
n = Total number of hospitalizations for which specific data was available. (Total number of hospitalizations in this study = 344.).
ID = Infectious disease specialist
Infectious disease diagnoses and co-morbidities in 344 hospitalizations among 216 IVDU*
| Types of infectious disease diagnoses†: | |
| Skin and soft tissue infection | 129 (37.5) |
| Pneumonia | 75 (21.8) |
| Endocarditis | 54 (15.7) |
| Bone and joint infections | 50 (14.5) |
| Septic thrombosis | 36 (10.5) |
| Primary sepsis without focus | 26 (7.6) |
| Various infections | 75 (21.8) |
| Number of simultaneous infections: | |
| one infection | 258 (75.0) |
| two infections | 70 (20.3) |
| three or more infections | 16 (4.7) |
| Number of hospitalizations where surgical intervention was required | 110 (32.0) |
| Comorbidities†: | |
| Major psychiatric disease | 52 (15.1) |
| Alcohol addiction | 55 (16.0) |
| Nicotin addiction | 265 (77.0) |
| HIV infection | 120 (34.9) |
| Chronic hepatitis B | 47 (13.7) |
| Hepatitis C | 268 (77.9) |
| Anemia | 157 (45.5) |
| Deep venous thrombosis (non-septic) | 23 (6.7) |
IVDU = Intravenous drug users.
* seen by an ID during a period of 5 years.
† 447 diagnoses among 344 hospital episodes. During one hospital episode more than one diagnosis and comorbidity can be documented
Pathogens identified and antibiotic therapies used in 344 hospitalizations among 216 IVDU*
| | 131‡ (38.1) |
| Beta-hemolytic streptococci | 42 (12.2) |
| Viridans streptococci | 30 (8.7) |
| Enterobacteriaceae | 17 (4.9) |
| | 14 (4.1) |
| | 10 (2.9) |
| Coagulase-negative staphylococci | 6 (1.7) |
| | 6 (1.7) |
| Other pathogens | 15 (4.4) |
| Polymicrobial infections | 64 (18.6) |
| No pathogen identified | 73 (21.2) |
| Beta-lactams | 292 (84.9) |
| Amoxicilline/Clavulanate | 129 (37.5) |
| Penicilline | 54 (15.7) |
| Flucloxacilline | 48 (14.0) |
| Cephalosporines | 33 (9.6) |
| Piperacilline/Tazobactam | 18 (5.2) |
| Carbapenemes | 10 (2.9) |
| Non-beta-lactams | |
| Aminoglycosides (used in combination) | 10 (2.9) |
| Fluoroquinolones | 8 (2.3) |
| Antituberculosis drugs | 6 (1.7) |
| Others | 28 (8.1) |
* seen by an ID during a period of 5 years.
† Antibiotic prescribed for the longest period intravenously during one hospitalization.
‡ Two of 131 (1.53%) S.aureus infections were due to methicillin-resistant S.aureus (MRSA).
Discharge data for 344 hospitalizations among 216 IVDU* for treatment of infectious diseases
| Discharge with oral antibiotics after adequate or best alternative therapy | 162 (47.1) |
| Discharge without antibiotics after adequate or best alternative therapy | 117 (34.0) |
| Discharge against medical advice, with oral antibiotics | 29 (8.4) |
| Discharge against medical advice, without antibiotic therapy | 13 (3.8) |
| Discharge without available follow-up data for antibiotic therapy | 1 (0.3) |
| In-hospital deaths† | 22 (6.4) |
| Total | 344 (100) |
| Readmissions | |
| < 30 days with relapse of original infection | 13 (3.8) |
| with infection but not relapse of original infection | 19 (5.5) |
| with no infection | 15 (4.4) |
| 30–90 days | 53 (15.4) |
| > 90 days | 100 (29.1) |
| Deaths overall (determined from state records for n = 199 patients) | 49 (24.6) |
| After discharge from hospital: not related to treated infection | 27 (13.6) |
| In-hospital (of cases): | |
| infection related | 18 (5.2) |
| not infection related | 4 (1.2) |
IVDU = Intravenous drug users.
* seen by an ID during a period of 5 years.
† Described in detail in the lower part of the table.
Risk factors associated with patient non-compliance and infection-related mortality (multiple logistic regression analysis) of 344 hospitalizations among 216 IVDU*
| Male gender | 1.2 (0.6–2.2) | 0.60 |
| Age (per 10 years older) | 0.8 (0.5–1.2) | 0.26 |
| Alcohol addiction | 0.8 (0.4–1.7) | 0.55 |
| Psychiatric disorders | 2.4 (1.1–5.1) | 0.03† |
| HIV infection | 0.7 (0.3–1.3) | 0.24 |
| Number of infections | 1.4 (0.7–2.9) | 0.32 |
| Age (per 10 years older) | 2.0 (1.0–3.8) | 0.04† |
| Male gender | 1.0 (0.4–2.6) | 0.93 |
| Number of comorbidities | 1.0 (0.8–1.3) | 0.95 |
* seen by an ID during a period of 5 years.
† Statistical significance (p < 0.05).